Nuwellis, Inc. (NASDAQ: NUWE) announced on July 30, 2026, that a new single-center retrospective study supporting the use of epoprostenol as an alternative anticoagulant during Aquadex ultrafiltration therapy has been accepted for publication in Frontiers in Pediatrics. The study addresses a critical gap in pediatric critical care by providing evidence for a safe anticoagulation strategy for children who cannot tolerate conventional therapies, thereby expanding the clinical utility of Nuwellis’ Aquadex system in intensive care units.

The research, titled "Epoprostenol as an Alternative Anticoagulant for Pediatric Aquadex Therapy: A Safe and Feasible Option," represents the first documented use of epoprostenol as the sole anticoagulant for children undergoing this specific ultrafiltration treatment. Published in a multi-disciplinary peer-reviewed journal focused on pediatric patient care, the findings offer real-world data to physicians managing complex cardiorenal conditions in critically ill children.

"Acceptance of a study in a respected peer-reviewed journal represents another important milestone in the expanding clinical evidence supporting Aquadex therapy in pediatric critical care," said Mike McCormick, CEO of Nuwellis. "As physicians care for increasingly complex pediatric patients, high-quality clinical evidence becomes essential to expanding confidence in Aquadex therapy."

Study Methodology and Patient Cohort

The retrospective analysis reviewed data from 46 children who underwent 52 treatment courses at UPMC Children’s Hospital of Pittsburgh. The treatment period spanned from September 2022 to September 2025. The study focused on critically ill pediatric patients requiring extracorporeal fluid removal, a procedure where maintaining the filtering circuit without causing bleeding is a significant clinical challenge.

Clinical Outcomes and Safety Profile

The study found that using epoprostenol, a short-acting drug that prevents platelet clumping, maintained the integrity of the filtering circuit without adverse safety signals. Key outcomes included steady or modestly rising platelet counts and no increase in the need for blood-pressure support. Crucially, no bleeding events were attributed to the drug during the treatment courses.

Dana Y. Fuhrman, DO, MS, the study’s senior author, noted the clinical utility of the findings. "For our sickest children, the usual ways of keeping these circuits open aren’t always good options. This study suggests epoprostenol could give us another tool at the bedside, one that doesn’t add to bleeding risk or require intensive metabolic monitoring."

Analytical Observation: Feasibility vs. Superiority

While the results are positive, the authors explicitly frame the findings as a feasibility report rather than proof of superiority over existing anticoagulants. The short half-life of epoprostenol means its effects wear off quickly when therapy stops, which may be advantageous for unstable patients but requires careful management. This distinction is vital for clinicians interpreting the data; the study confirms safety and feasibility but does not establish epoprostenol as the definitive standard of care compared to heparin or other agents.

Financial Support and Disclosures

Nuwellis provided modest financial support to the study site specifically to underwrite the cost of open-access publication for the paper. The company stated it provided no funding for the conduct of the research itself, ensuring the clinical evaluation remained independent of corporate influence regarding trial design or data collection.

About Aquadex Therapy

The Aquadex SmartFlow System is indicated for continuous ultrafiltration therapy in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. Its low extracorporeal blood volume makes it particularly suitable for pediatric patients who may not tolerate traditional renal replacement therapies. All treatments must be administered by trained healthcare providers within a clinical setting under physician prescription.

Nuwellis Inc. shares surged 89.97% to $3.59 in after-hours trading on Wednesday, driven by the company’s announcement that it installed its first Aquadex SmartFlow systems at a leading pediatric hospital in Wisconsin. This milestone marks a significant expansion into the pediatric critical care market for the Minnesota-based medical technology firm. The stock move comes alongside preliminary second-quarter results showing 14% year-over-year revenue growth, reinforcing investor confidence in the company’s commercial momentum despite a broader long-term downtrend.

The installation represents Nuwellis’s entry into a key segment within its largest customer category. CEO Mike McCormick stated that the Wisconsin deployment reflects "continued momentum" in pediatric growth and "increasing clinical adoption" of Aquadex therapy. He noted that this collaboration enables Nuwellis to establish clinical protocols and workflows, supporting broader use of the therapy over time. The Aquadex SmartFlow device is indicated for adult and pediatric patients weighing 20 kilograms or more who have not responded to diuretics, used to remove excess salt and water from patients with fluid overload.

Trading Activity and Market Context

The rally followed an exceptionally volatile regular trading session where NUWE was down 2.07% at $1.89. Wednesday’s volume reached 11.68 million shares, which is more than 70.57 times the stock’s average daily volume of 165,510 shares. Despite the sharp after-hours gain, the stock remains near its 52-week low of $1.83, having declined 99.49% over the past 12 months. The Relative Strength Index (RSI) stands at 17.56, indicating oversold conditions, while Benzinga’s Edge Stock Rankings cite a negative price trend across all time periods.

Financial Outlook

Nuwellis reported preliminary revenue growth of 14% year-over-year for Q2 and 20% for the six-month period ended June 30. Full financial results, including net profit and EBITDA details, are scheduled for release before the open of U.S. markets on August 13. Management will host a conference call and webcast at 9:00 a.m. Eastern time on that date to discuss the findings. The disparity between Q2 and H2 growth rates suggests accelerating traction in the latter part of the fiscal cycle, potentially aided by new clinical adoptions like the Wisconsin hospital deal.

What the Numbers Show

The juxtaposition of a near-90% single-day stock surge against a 99.49% decline over the past year highlights extreme volatility and speculative interest in Nuwellis. While the preliminary revenue figures confirm operational improvement, the stock’s valuation remains heavily influenced by discrete clinical milestones rather than broad financial metrics. The successful entry into the pediatric market serves as a tangible proof point for the utility of Aquadex SmartFlow beyond adult care, potentially reducing dependency on a single patient demographic as the company scales.